Docket Number:28A-1030319
Inventor:Chung-Hsuan Chen、Bai-Ling Lin、Chin-Yu Wang
IP Status:TW I546381、JP 6313478、US 9976146 B2
Abstract:
We identified a DNA aptamer against a shared tumor-specific peptide antigen of MAGE-A3 which is one of the most frequently and highly expressed CTAs in multiple tumors. This is the first demonstration that a peptide antigen resided in the binding cleft of a MHC molecule on the cell surface can be targeted by an aptamer. Currently, a considerable number of shared tumor-specific peptide antigens are known. The same principle can be applied to identify aptamers against these antigens. The aptamers will be able to target multiple tumors.
Fields of Application:
The aptamers against shared tumor-specific antigens can be developed into nearly “universal” therapeutics and diagnostic products for multiple types of cancer.
Advantages when compared to the existing technologies:
Shared tumor-specific antigens, or often called “cancer/testis antigens” (CTAs), are small peptide fragments of cellular proteins that are presented at the surface of a wide variety of tumor cells by the major histocompatibility complex (MHC) molecules that are recognized by helper or cytotoxic T lymphocyte. CTAs have been used for developing cancer vaccines. Aptamers are functional nucleic acid molecules that fold into well-defined structures and bind to a wide range of molecular targets with high affinity and specificity. Aptamers with specific sequences can be obtained by “Systematic Evolution of Ligands by Exponential Enrichment” (SELEX), and have been developed as therapeutics against specific targets.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
